927 studies found for:    Open Studies | "Carcinoma, Bronchogenic"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Carcinoma, Bronchogenic"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting SAS in Patients With Bronchial Carcinoma
Conditions: Sleep Apnea Syndrome;   Bronchial Carcinoma
Intervention: Device: sleep apnea screening with ApneaLinkTM
2 Recruiting Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics
Conditions: Tumors;   Carcinoma, Bronchogenic;   Breast Carcinoma;   Cancer of Head and Neck;   Lymphoma, Malignant;   Soft Tissue Neoplasms
Intervention: Drug: 18F-Al-NOTA-PRGD2 PET/CT
3 Unknown  Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy
Condition: Squamous Cell Carcinoma of Bronchus
Intervention: Drug: Gefitinib
4 Unknown  Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)
Condition: Recurrent Small Cell Lung Cancer
Intervention: Drug: Bendamustin/Ribomustin
5 Recruiting Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer
Conditions: Stage IA Non-small Cell Lung Cancer;   Adenocarcinoma of the Lung;   Squamous Cell Lung Cancer
Intervention:
6 Recruiting Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
Conditions: Lung Cancer;   Non-small Cell Lung Cancer (NSCLC)
Interventions: Drug: Dasatinib - 1A;   Drug: Afatinib - 1A;   Drug: Dasatinib - 1B;   Drug: Afatinib - 1B
7 Not yet recruiting Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma
Condition: ALK-positive Non-small Cell Lung Cancer
Interventions: Drug: Ceritinib;   Radiation: Stereotactic ablative body radiation
8 Recruiting Endu Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research
Condition: Non-small Cell Lung Cancer
Interventions: Biological: Endostar;   Drug: Changchun marina;   Drug: cisplatin;   Drug: Taxol;   Drug: parapl
9 Not yet recruiting LIquid BIopsies in Lung Cancer (LIBIL)
Condition: Carcinoma, Non-small Cell Lung
Intervention:
10 Not yet recruiting Crizotinib Plus Pembrolizumab In Alk-positive Advanced Non Small Cell Lung Cancer Patients
Condition: ALK-positive Advanced NSCLC
Interventions: Drug: Crizotinib;   Drug: Pembrolizumab
11 Not yet recruiting AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
Condition: Stage IB-IIIA Non-small Cell Lung Carcinoma, With a Centrally Confirmed, Common Sensitising EGFR Mutations
Interventions: Drug: AZD9291 80 mg/40 mg;   Drug: Placebo AZD9291 80 mg/40 mg
12 Recruiting Role of PET Scan in the Evaluation of Early Response to Maintenance Treatment in Advanced Non-small-cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Intervention: Device: PET scan imaging
13 Recruiting Docetaxel + Plinabulin vs Docetaxel as 2nd-Line Chemo in Patients With Advanced NSCLC With >1 Large Lung Lesion
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Plinabulin (DP);   Drug: Docetaxel (D)
14 Not yet recruiting Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)
Condition: Non-small Cell Lung Cancer
Interventions: Biological: pembrolizumab;   Other: Placebo
15 Recruiting AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies
Conditions: Lung Cancer;   Targeted Therapy
Intervention: Drug: AZD9291
16 Not yet recruiting TORC1/2 Inhibitor INK128 and EGFR Inhibitor AZD9291 in Treating Patients With Advanced EGFR Mutation Positive Non-small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
Conditions: Recurrent Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: EGFR Inhibitor AZD9291;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: TORC1/2 Inhibitor INK128
17 Not yet recruiting Selumetinib and Nab-Paclitaxel (Albumin-stabilized Nanoparticle Formulation) as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
Conditions: Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation;   Other: Pharmacological Study;   Drug: Selumetinib
18 Not yet recruiting Echocardiography for RILI Prediction
Condition: NSCLC
Intervention:
19 Recruiting A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations
Condition: EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations
Interventions: Drug: ASP8273 Capsules;   Drug: ASP8273 Capsules A
20 Recruiting SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma
Conditions: Small Cell Lung Cancer;   Large Cell Neuroendocrine Carcinoma
Intervention: Drug: SC-002

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years